### **Overview** Sai Life Sciences Ltd is a globally recognized, integrated **Contract Research, Development, and Manufacturing Organization (CRDMO)** headquartered in Hyderabad, India. Since its founding in 1999, the company has evolved from a chemistry services provider into a fully integrated end-to-end partner for pharmaceutical and biotech innovators worldwide. It serves over **300 clients**, including **18 of the top 25 global pharmaceutical companies**, across the US, UK, EU, and Japan. The company operates under a **"follow-the-molecule" model**, enabling seamless progression from early drug discovery through clinical development to commercial manufacturing. It differentiates itself through scientific depth, operational agility, technological innovation, and a globally distributed footprint that combines high-touch customer engagement with cost-competitive scalability. --- ### **Strategic Positioning & Business Model** Sai Life Sciences operates across two core verticals: 1. **Discovery (CRO)** – Integrated drug discovery services including medicinal chemistry, biology, DMPK, toxicology, and IND-enabling studies. 2. **Chemistry, Manufacturing & Controls (CMC)** – Full-spectrum CDMO services covering process development, GMP manufacturing of APIs and intermediates, formulation, and clinical supply. The company generates revenue through: - **Fee-for-Service (FFS)**: For discrete R&D or manufacturing projects. - **Full-Time Equivalent (FTE) & Integrated Partnerships**: Long-term collaborations, including dedicated R&D centers co-located with client teams. Its business is not dependent on drug approval outcomes, reducing binary risk and ensuring stable, recurring revenues based on scientific execution and partnership longevity. The average client relationship duration exceeds **10 years**, reflecting exceptional retention and trust. --- ### **Global Capabilities & Infrastructure** Sai Life Sciences leverages a **globally connected operating model**: - **R&D Hubs**: Boston, USA (Discovery Biology); Manchester, UK (Process Chemistry Center of Excellence); Hyderabad, India (Integrated Discovery & Development). - **Manufacturing Sites**: Unit II (Hyderabad), Unit IV (Bidar) – both compliant with USFDA, PMDA (Japan), and COFEPRIS (Mexico); and Manchester, UK (clinical-scale manufacturing). The company has **~700 kiloliters** of installed manufacturing capacity and maintains **over 3,400 employees**, of which **over 2,600 are scientists** with an average experience of 8+ years. This deep scientific talent pool supports complex chemistry such as chemo- and bio-catalysis, flow chemistry, cryogenic reactions, and HPAPIs. Key facilities: - **Unit II, Hyderabad**: 12-acre integrated discovery & development campus with 199 chemistry labs, clinical manufacturing, and a **dedicated Peptide Research Center** launched in April 2025. - **Unit IV, Bidar**: Flagship manufacturing site with 12 production blocks; dedicated HPAPI, amidites, lyophilization, and cleanroom capabilities. - **Manchester, UK**: 20,000 sq. ft. facility focused on advanced process R&D, cGMP kilo labs, and technology transfer. - **Boston, USA**: Statutory biological laboratory supporting discovery biology and integrated programs. --- ### **Recent Strategic Developments (2024–2025)** #### **1. New CMC Process R&D Center (Oct 2025)** In October 2025, Sai Life Sciences launched a **new CMC Process R&D Center in Hyderabad**, a strategic capital investment aimed at: - Doubling process R&D capacity by **September 2026**. - Expanding into **peptide APIs**, **oligonucleotide intermediates**, **ADC linkers**, and **early-phase clinical supply**. - Featuring **140 fume hoods**, **dedicated peptide/oligo labs**, and a **25,000 sq. ft. centralized analytical lab**. - Supporting **FTE and Dedicated Project Capacity (DPC)** models for flexible client collaboration. This reinforces Sai’s position as a preferred partner for **late-stage and commercial-scale CMC programs** amid rising demand. #### **2. Veterinary API Facility Investment (Sep 2025)** The company is building a dedicated **veterinary API manufacturing facility**, tapping into a high-growth, high-margin niche. It leverages existing API expertise, quality systems, and advanced process technologies to serve the expanding animal healthcare market. #### **3. Dedication to Emerging Therapeutic Modalities** Sai is strategically expanding into next-generation modalities: - **Peptides**: Full lifecycle support from discovery to scale-up; Peptide Research Center launched in 2024. - **Oligonucleotides**: Focus on **amidite production** for nucleic acid therapeutics. - **Antibody-Drug Conjugates (ADCs)**: Enhancing conjugation capabilities and upgrading to **Class 6 containment**. - **Targeted Protein Degraders (TPDs), mRNA, Cell & Gene Therapy (CGT)**: Early-stage investments underway. - **GLP-1 Peptide Space**: Active involvement in clinical-stage molecule development. --- ### **Technology & Digital Transformation** Technology is core to Sai’s competitive edge: - **Digital Lab Infrastructure**: Electronic lab notebooks, paperless QMS, real-time data acquisition. - **AI & Machine Learning**: Deployed in retrosynthesis, route optimization, and CADD (Computer-Aided Drug Design). - **Automation**: High-throughput experimentation, automated liquid handling in DMPK and biology labs. - **Proprietary GMP Digital Platform**: Integrates R&D, manufacturing, and quality systems for traceability, compliance, and efficiency. The company is also associated with **Schrödinger** for advanced computational drug discovery. --- ### **Sustainability & ESG Leadership** Sai Life Sciences is a leader in green manufacturing: - Unit IV (Bidar) uses **89% green energy** in FY24, powered by a **2.7 MW wind turbine**. - Facilities certified under **ISO 14001, ISO 45001, ISO 50001**, and **ISO 27001**. - Member of the **ACS Green Chemistry Institute Pharmaceutical Roundtable** and first Indian company to join the **Pharmaceutical Supply Chain Initiative (PSCI)**. - Actively reducing dependency on Chinese sourcing—from 33% to 28%—to strengthen supply chain resilience. --- ### **Financial & Growth Highlights** - **Revenue CAGR (FY22–FY25): 25%**, growing from ₹870 crore to ₹1,695 crore. - **FY25 Revenue Mix**: 37% CRO, 63% CDMO. - **Pipeline**: Over **160 active programs**, including: - **30 commercial molecules** - **6 in Phase III / Pre-registration** - **40+ advanced to IND or clinical trials** - **25+ molecules from discovery to market launch** - **Capital Expenditure**: ₹700 crore planned for **FY26**, funding: - Second manufacturing site in Hyderabad. - New Process R&D Block and veterinary API facility. - Expansion of peptide, oligo, and ADC capabilities. --- ### **Leadership & Governance** - **Managing Director & CEO**: **Krishnam Raju Kanumuri** (joined 2004), credited with transforming Sai into a global CRDMO. - Spearheaded IPO in **December 2024** at ₹549/share; stock rose to ₹846.3 by July 2025. - Led global expansion (Boston, Manchester), strategic M&A, and commercial growth. - Leadership team averages **25+ years** of global CRDMO experience. - **16-person global BD team** across US, UK, Europe, and India to deepen client engagement. --- ### **Key Strengths** | Strength | Details | |--------|--------| | **Vertically Integrated Platform** | Seamless discovery-to-manufacturing continuum with no handoff delays | | **Regulatory Track Record** | 100% success rate in USFDA and PMDA inspections | | **Client Stickiness** | 65%+ discovery revenue from multi-service clients; 10-year avg. relationship | | **Technological Agility** | AI/ML, automation, digital systems embedded across operations | | **Sustainability** | Industry-leading green energy adoption and ESG commitments | | **Strategic Partnerships** | Integrated model with **Agility Life Sciences** (formulation) and **Centrix Pharma** (clinical manufacturing) | --- ### **Strategic Priorities for FY26** 1. **Double process R&D capacity** with new Hyderabad center. 2. **Scale commercial manufacturing** through new facility and added capacity. 3. **Expand in emerging modalities**: peptides, ADCs, oligonucleotides. 4. **Enhance digital and automation platforms** for efficiency. 5. **Deepen long-term client partnerships** through integrated models. 6. **Strengthen supply chain resilience** with diversified sourcing and indigenous raw material development. ---